77
Participants
Start Date
March 15, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
HST-1011
HST-1011 given orally
Cemiplimab
Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally
Memorial Sloan Kettering Cancer Center, New York
Montefiore Einstein Comprehensive Cancer Center, The Bronx
University of Pittsburgh (UPMC), Hillman Cancer Center, Pittsburgh
Abramson Cancer Center, Philadelphia
Florida Cancer Specialists, Sarasota
The University of Texas MD Anderson Cancer Center, Houston
Comprehensive Cancer Centers of Nevada, Las Vegas
Providence Cancer Institute of Oregon, Portland
University of Ottawa, Ottawa
Princess Margaret Cancer Center, Toronto
NEXT Oncology Barcelona IOB Hospital Quirónsalud, Barcelona
Clínica Universidad de Navarra, Madrid
NEXT Oncology Hospital Universitario Quirónsalud Madrid, Madrid
Clínica Universidad de Navarra (Pamplona), Pamplona
Lead Sponsor
HotSpot Therapeutics, Inc
INDUSTRY